Penumbra Inc. (NYSE: PEN) saw its stock surge 5.66% in after-hours trading on Tuesday following the release of its impressive second-quarter 2025 financial results and an upward revision of its full-year revenue guidance.

The medical device company reported Q2 revenue of $339.5 million, representing a 13.4% increase from the same period last year and surpassing the analyst consensus estimate of $327.7 million. Penumbra's adjusted earnings per share came in at $0.86, beating the expected $0.82 per share. The company's net income for the quarter stood at $45.3 million, with an adjusted EBITDA of $61.4 million.

Notably, Penumbra's U.S. market performance was particularly strong, with revenue rising 19.5% and accounting for 76.8% of total revenue. The company's U.S. thrombectomy revenue saw a robust increase of 22.6%, while U.S. VTE revenue surged by an impressive 42% compared to the same period last year. In light of these strong results, Penumbra raised its full-year 2025 revenue guidance to a range of $1.355 billion to $1.370 billion, indicating an anticipated growth of 13% to 15% over 2024 revenue. The company also maintained its forecast for U.S. thrombectomy growth of 20% to 21% compared to 2024 levels, further boosting investor confidence in its growth prospects.